Kutatási jelek – Signal Engine

• Molecular heterogeneity of ERBB2-altered cancers: A pan‑cancer landscape across US and Japanese cohorts — Breast cancer
• Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies — Renal cell carcinoma
• Trial design and end points in hepatocellular carcinoma: an EASL – AASLD – ILCA consensus statement — Hepatocellular carcinoma
• Can natural killer cells cure leukemia? — Leukemia
• First-line treatment strategies for BRAF-V600E mutated non-small cell lung cancer: lessons from real-world data and ongoing uncertainties — NSCLC
• Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies — NSCLC
• Dual CAR‑NK cells targeting PD‑L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity — Breast cancer
• APR-246 drives ROS‑dependent ferroptosis and apoptosis and enhances anti‑PD‑1 efficacy in bladder cancer — Bladder cancer
• TRIM26-mediated NKRF degradation drives Osimertinib resistance through SNRPD2-dependent stress granule formation in lung adenocarcinoma — NSCLC
• Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer — Colorectal cancer
• Exploring the putative role of EGFR in prostate cancer: Interactions with androgen and estrogen receptors — Prostate cancer
• EGFR- and HER3-targeted bispecific antibody‑drug conjugate demonstrates antitumor activity in metastatic castration‑resistant prostate cancer — Prostate cancer
• An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR‑ERBB2 heterodimerization — Prostate cancer
• BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co‑Mutation Patterns, and Clinical Relevance — Melanoma
• Genomic landscape and precision therapy in prostate cancer: current status and future directions — Prostate cancer
• TP53 mutations in triple‑negative breast cancer cells confer sensitivity to ASCT2 inhibition via arginine uptake — Breast cancer
• The TP53 p.R337H Germline Variant and Breast Cancer: Prevalence from a Cohort Study and Structured Literature Review — Breast cancer
• Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers — Breast cancer
• Mutant p53 epigenetically rewires CXCL10 to promote CD8+ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer — Prostate cancer
• TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion — NSCLC